As of 2024-10-14, the Relative Valuation of Bristol-Myers Squibb Co (BMY) is (10.40) USD. This relative valuation is based on P/E multiples. With the latest stock price at 52.67 USD, the upside of Bristol-Myers Squibb Co based on Relative Valuation is -119.8%.
The range of the Relative Valuation is (64.27) - 109.59 USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.9x - 32.8x | 30.0x |
| Forward P/E multiples | 16.5x - 30.0x | 20.8x |
| Fair Price | (64.27) - 109.59 | (10.40) |
| Upside | -222.0% - 108.1% | -119.8% |
| Date | P/E |
| 2024-10-14 | -16.33 |
| 2024-10-11 | -16.18 |
| 2024-10-10 | -16.24 |
| 2024-10-09 | -16.37 |
| 2024-10-08 | -16.27 |
| 2024-10-07 | -16.56 |
| 2024-10-04 | -16.73 |
| 2024-10-03 | -16.80 |
| 2024-10-02 | -16.66 |
| 2024-10-01 | -16.40 |
| 2024-09-30 | -16.04 |
| 2024-09-27 | -15.78 |
| 2024-09-26 | -15.53 |
| 2024-09-25 | -15.48 |
| 2024-09-24 | -15.79 |
| 2024-09-23 | -15.50 |
| 2024-09-20 | -15.31 |
| 2024-09-19 | -15.19 |
| 2024-09-18 | -15.42 |
| 2024-09-17 | -15.34 |
| 2024-09-16 | -15.49 |
| 2024-09-13 | -15.23 |
| 2024-09-12 | -14.95 |
| 2024-09-11 | -15.06 |
| 2024-09-10 | -15.27 |
| 2024-09-09 | -15.03 |
| 2024-09-06 | -15.09 |
| 2024-09-05 | -15.44 |
| 2024-09-04 | -15.49 |
| 2024-09-03 | -15.66 |
| 2024-08-30 | -15.48 |
| 2024-08-29 | -15.41 |
| 2024-08-28 | -15.21 |
| 2024-08-27 | -14.91 |
| 2024-08-26 | -14.95 |
| 2024-08-23 | -14.91 |
| 2024-08-22 | -14.76 |
| 2024-08-21 | -15.01 |
| 2024-08-20 | -15.18 |
| 2024-08-19 | -15.28 |
| 2024-08-16 | -15.30 |
| 2024-08-15 | -15.22 |
| 2024-08-14 | -15.00 |
| 2024-08-13 | -15.21 |
| 2024-08-12 | -14.59 |
| 2024-08-09 | -14.48 |
| 2024-08-08 | -14.52 |
| 2024-08-07 | -14.41 |
| 2024-08-06 | -14.66 |
| 2024-08-05 | -14.75 |